All content on this site is intended for healthcare professionals only. By acknowledging this message and accessing the information on this website you are confirming that you are a Healthcare Professional.
The GvHD Hub uses cookies on this website. They help us give you the best online experience. By continuing to use our website without changing your cookie settings, you agree to our use of cookies in accordance with our updated Cookie Policy
Introducing
Now you can personalise
your GvHD Hub experience!
Bookmark content to read later
Select your specific areas of interest
View content recommended for you
Find out moreThe GvHD Hub website uses a third-party service provided by Google that dynamically translates web content. Translations are machine generated, so may not be an exact or complete translation, and the GvHD Hub cannot guarantee the accuracy of translated content. The GvHD Hub and its employees will not be liable for any direct, indirect, or consequential damages (even if foreseeable) resulting from use of the Google Translate feature. For further support with Google Translate, visit Google Translate Help.
Symposium | The long-term burden of cGvHD
Featured
Video series
GvHD Hub EBMT Symposium 2024: 30 years of ECP in GvHD: Recommendations for the treatment of cGvHD
Test your knowledge! Take our quick quiz before and after you read this article to find out if you improved your knowledge. Results help us to improve content and continually provide open-access education.
On April 14, 2024, the GvHD Hub held a symposium at the 50th European Society for Bone and Marrow Transplantation (EBMT) Annual Meeting on the role of extracorporeal photopheresis (ECP) in the management of chronic graft-versus-host disease (cGvHD).
Here, we share the presentation by Bipin Savani, Vanderbilt University Medical Center, Nashville, US, which explored the long-term burden of cGvHD. Savani discussed organs frequently affected by cGvHD (Figure 1), comorbidities and mortality in patients with cGvHD (Figure 2), and recent progress made in improving the safety of transplantation. He highlighted that mental health disorders, such as anxiety and depression, are prevalent in patients with cGvHD and that the physical burden of symptoms contributes to limitation of daily activities in these patients.
Figure 1. Proportion of patients experiencing mouth, skin, liver, and eye symptoms of cGvHD*
cGvHD, chronic graft-versus-host disease.
*Data from Kurosawa et al.1 and Arora et al.2
Figure 2. Causes of death in long-term survivors of cGvHD*
cGvHD, chronic graft-versus-host disease.
*Adapted from Martin et al.3
Q&A session
This symposium closed with a panel Q&A session with live audience participation, where our panelists shared their perspectives on the value and challenges of ECP in pediatric patients.
Symposium | Q&A | Value and challenges of ECP in pediatric patients
Symposium | The long-term burden of cGvHD
- Kurosawa S, Oshima K, Yamaguchi T, et al. Quality of life after allogeneic hematopoietic cell transplantation according to affected organ and severity of chronic graft-versus-host disease. Biol Blood Marrow Transplant. 2017;23(10):1749-1758. DOI: 10.1016/j.bbmt.2017.06.011
- Arora M, Cutler CS, Jagasia MH, et al. Late acute and chronic graft-versus-host disease after allogeneic hematopoietic cell transplantation. Biol Blood Marrow Transplant. 2016;22(3):449-455. DOI: 10.1016/j.bbmt.2015.10.018
- Martin PJ, Counts Jr GW, Appelbaum FR, et al. Life expectancy in patients surviving more than 5 years after hematopoietic cell transplantation. J Clin Oncol. 2010;28(6):1011-1016. DOI: 10.1200/JCO.2009.25.6693
Video series
GvHD Hub EBMT Symposium 2024: 30 years of ECP in GvHD: Recommendations for the treatment of cGvHD
Your opinion matters
3 votes - 61 days left ...
Newsletter
Subscribe to get the best content related to GvHD delivered to your inbox